Bluebird Bio Inc., of Cambridge, Mass., said the first subject with beta-thalassemia major was enrolled in its phase I/II Northstar Study (HGB-204) and has undergone infusion with the company’s Lentiglobin drug product in an autologous hematopoietic stem cell transplantation.